Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ARK Space & Defense Innovation ETF (ARKX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ARK Space & Defense Innovation ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while ARK Space & Defense Innovation ETF trades at $34.73. The key difference: ARK Space & Defense Innovation ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ARKX | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $37.74 |
52-Week Low | $205.48 | $25.46 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
ARKX trades at $34.69, up 0.81% with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on space and defense innovation, with key holdings like SpaceX and Rocket Lab. Recent news highlights strong interest in space economy ETFs as alternatives to direct SpaceX investment, with ARKX noted for outperforming peers in one-year returns despite higher volatility.
The outlook for ARKX is positive due to growing space industry tailwinds, but risks include high expense ratios and volatility. Investment appeal lies in diversified exposure to disruptive tech, though valuation concerns for holdings like SpaceX and competitive ETF options warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →
